SM 130686
Alternative Names: SM-130686Latest Information Update: 08 Feb 2008
At a glance
- Originator Dainippon Sumitomo Pharma
- Class
- Mechanism of Action Growth hormone releasing factor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Dwarfism
Most Recent Events
- 08 Feb 2008 Discontinued for Dwarfism in Japan (PO)
- 01 Oct 2005 Sumitomo Pharmaceuticals has merged with Dainippon Pharmaceutical to form Dainippon Sumitomo Pharma
- 21 Sep 2000 Early research for Dwarfism in Japan (PO)